Compare FUNC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUNC | IKT |
|---|---|---|
| Founded | 1900 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 274.9M |
| IPO Year | 2012 | 2020 |
| Metric | FUNC | IKT |
|---|---|---|
| Price | $43.81 | $1.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $50.00 | $6.00 |
| AVG Volume (30 Days) | 27.9K | ★ 542.5K |
| Earning Date | 10-23-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | 19.68 | ★ 57.76 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $18,426,000.00 | N/A |
| Revenue This Year | $9.57 | N/A |
| Revenue Next Year | $6.10 | $33.33 |
| P/E Ratio | $22.84 | ★ N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $33.54 | $1.33 |
| 52 Week High | $46.30 | $2.61 |
| Indicator | FUNC | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 30.76 |
| Support Level | $43.30 | $1.59 |
| Resistance Level | $45.71 | $1.91 |
| Average True Range (ATR) | 1.12 | 0.10 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 45.13 | 1.04 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.